Literature DB >> 11298143

Evaluation of six commercial assays for the rapid detection of Clostridium difficile toxin and/or antigen in stool specimens.

H Vanpoucke1, T De Baere, G Claeys, M Vaneechoutte, G Verschraegen.   

Abstract

OBJECTIVE: To evaluate six commercially available assays for the detection of Clostridium difficile toxin and/or antigen in stool samples: one latex agglutination test (Culturette brand CDT, Becton Dickinson), two ELISAs (Culturette brand Toxin CD, Becton Dickinson, and Ridascreen C. difficile Toxin A/B, R-biopharm), two chromatographic assays (Clearview C. difficile A, Oxoid, and ColorPac Toxin A, Becton Dickinson) and one enzyme immunoassay for the simultaneous detection of C. difficile common antigen and toxin A (Triage C. difficile Panel, Biosite).
METHODS: Over a period of 3 months, 366 liquid or semi-liquid stool samples were tested using cell-culture cytotoxin assay as standard, ethanol shock stool culture and latex agglutination (Culturette brand CDT). Of these, 78 samples, positive with at least one of these three methods, and 98 randomly selected negative samples were further evaluated using the other five kits. PCR was also performed on positive cultures to confirm the presence of toxin A and B genes.
RESULTS: Triage C. difficile Panel had the best sensitivity (95%), followed by Clearview C. difficile and ColorPac Toxin A (both 89%), Culturette brand Toxin CD (73%), Ridascreen C. difficile Toxin A/B (57%) and Culturette brand CDT (23%). For Triage, the sensitivity of C. difficile antigen detection was 93%, and the sensitivity of toxin detection was lower (77%). Most false-positive results were obtained with the Triage C. difficile Panel (25 specimens) and Clearview C. difficile A (20 specimens). Culturette brand CDT had the best specificity (99%); followed by Ridascreen C. difficile Toxin A/B (97%), Culturette brand Toxin CD (95%), ColorPac Toxin A (89%), Clearview C. difficile A (83%) and Triage C. difficile Panel (75%). The positive predictive values ranged from 68% to 94%, and the negative predictive values from 83% to 98%.
CONCLUSIONS: The sensitivity is much higher for Triage and the two new chromatographic assays than for the conventional EIAs. These tests also have a high negative predictive value. For Triage, C. difficile antigen-positive, toxin A-negative results can be obtained; the clinical value of these must be established by additional studies. Overall, the new-generation assays are still less sensitive than the cytotoxin assay; however, they provided same-day results, could be used as a screening test and may be useful in laboratories without tissue-culture facilities. Our results do not allow the recommendation of one single assay for the diagnosis of C. difficile-associated diarrhea. It remains the case that laboratory results must be correlated and interpreted with the clinical presentation of the patient.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11298143     DOI: 10.1046/j.1469-0691.2001.00141.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  17 in total

1.  Detection of Clostridium difficile toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assay.

Authors:  Daniel M Musher; Atisha Manhas; Pranav Jain; Franziska Nuila; Amna Waqar; Nancy Logan; Bernard Marino; Edward A Graviss
Journal:  J Clin Microbiol       Date:  2007-06-13       Impact factor: 5.948

2.  A case of severe pseudomembranous colitis diagnosed by colonoscopy after Helicobacter pylori eradication.

Authors:  Satoshi Sato; Daisuke Chinda; Kiyonori Yamai; Ryu Satake; Yasushi Soma; Tadashi Shimoyama; Shinsaku Fukuda
Journal:  Clin J Gastroenterol       Date:  2014-05-08

3.  Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of Clostridium difficile-associated diarrhea.

Authors:  D O'Connor; P Hynes; M Cormican; E Collins; G Corbett-Feeney; M Cassidy
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

Review 4.  Laboratory Tests for the Diagnosis of Clostridium difficile.

Authors:  Karen C Carroll; Masako Mizusawa
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

5.  Multicenter evaluation of the Quidel Lyra Direct C. difficile nucleic acid amplification assay.

Authors:  Eric T Beck; Blake W Buchan; Katherine M Riebe; Brenda R Alkins; Preeti Pancholi; Paul A Granato; Nathan A Ledeboer
Journal:  J Clin Microbiol       Date:  2014-03-26       Impact factor: 5.948

6.  Six rapid tests for direct detection of Clostridium difficile and its toxins in fecal samples compared with the fibroblast cytotoxicity assay.

Authors:  David K Turgeon; Thomas J Novicki; John Quick; LaDonna Carlson; Pat Miller; Bruce Ulness; Anne Cent; Rhoda Ashley; Ann Larson; Marie Coyle; Ajit P Limaye; Brad T Cookson; Thomas R Fritsche
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

7.  Performance of the TechLab C. DIFF CHEK-60 enzyme immunoassay (EIA) in combination with the C. difficile Tox A/B II EIA kit, the Triage C. difficile panel immunoassay, and a cytotoxin assay for diagnosis of Clostridium difficile-associated diarrhea.

Authors:  Heather Snell; Meredith Ramos; Sue Longo; Michael John; Zafar Hussain
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

8.  Evaluation of a new commercial TaqMan PCR assay for direct detection of the clostridium difficile toxin B gene in clinical stool specimens.

Authors:  Paul D Stamper; Wisal Babiker; Romina Alcabasa; Deborah Aird; Jennifer Wehrlin; Ijeoma Ikpeama; Linda Gluck; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2009-10-21       Impact factor: 5.948

Review 9.  Clostridium difficile-associated diarrhea in adults.

Authors:  Susan M Poutanen; Andrew E Simor
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

Review 10.  Clostridium difficile associated infection, diarrhea and colitis.

Authors:  Perry Hookman; Jamie S Barkin
Journal:  World J Gastroenterol       Date:  2009-04-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.